Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Lucentis® (ranibizumab) – New Indication
January 5, 2017 – Genentech announced the FDA approval of Lucentis (ranibizumab) for the treatment of patients with myopic choroidal neovascularization (mCNV).
